Lawrence J. Jasinski, a director at LeMaitre Vascular Inc . (NASDAQ:LMAT), recently sold 198 shares of the company's common stock. The transaction, dated November 20, 2024, was executed at a price of $103.50 per share, totaling approximately $20,493. Following this sale, Jasinski retains ownership of 5,111 shares in the company. This transaction was disclosed in a regulatory filing submitted to the Securities and Exchange Commission.
In other recent news, LeMaitre Vascular reported a robust Q3 performance, with a 16% increase in sales and a significant 49% rise in earnings per share (EPS). Growth was driven by key product categories, including grafts, patches, and carotid shunts, and strong sales in the APAC region, particularly in Thailand and Korea. The company is planning to expand its sales force and establish new international offices.
In terms of future developments, LeMaitre Vascular anticipates a gross margin of 68% for Q4 and operating income reaching $13.3 million. The company is also actively seeking larger acquisitions that align strategically with their business model. However, regulatory delays for allograft devices in Germany and Ireland have pushed their expected launch to 2025 or 2026.
Despite these challenges, the company maintains a positive outlook with projections of a 14% sales growth for Q4 2024 and an increase in the operating margin for the full year to 24%. The company's plans also include hiring more sales representatives and receiving the remaining MDR CE marks in 2025.
InvestingPro Insights
LeMaitre Vascular Inc. (NASDAQ:LMAT) has been experiencing significant growth and investor interest, as evidenced by its recent stock performance and financial metrics. According to InvestingPro data, the company's stock has shown a remarkable 100.07% total return over the past year, with a 21.5% return in just the last month. This strong performance has pushed LMAT's stock price to 99.89% of its 52-week high, reflecting robust investor confidence.
The company's financial health appears solid, with revenue growth of 14.81% in the last twelve months as of Q3 2024, reaching $213.03 million. LeMaitre's profitability is also noteworthy, with a gross profit margin of 68.34% and an operating income margin of 23.29% for the same period.
InvestingPro Tips highlight that LeMaitre has raised its dividend for 14 consecutive years, demonstrating a commitment to shareholder returns. This is particularly impressive given that the company operates with a moderate level of debt and maintains liquid assets that exceed short-term obligations.
However, investors should note that LMAT is trading at a high P/E ratio of 58.04, which may indicate that the stock is priced at a premium compared to its earnings. This valuation metric aligns with another InvestingPro Tip suggesting that the company is trading at a high earnings multiple.
For those interested in a deeper analysis, InvestingPro offers 19 additional tips for LeMaitre Vascular, providing a comprehensive view of the company's financial position and market performance.
The recent insider sale by director Lawrence J. Jasinski, while notable, should be considered in the context of these broader financial indicators and the company's strong market position. As always, investors are encouraged to conduct thorough research and consider multiple factors when making investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.